Self-administration of rozanolixizumab, a neonatal Fc receptor blocker (FcRn) indicated for generalized myasthenia gravis, ...
Zongertinib received FDA approval for HER2-mutant NSCLC, showing efficacy in first-line treatment with a 77% objective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback